

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



偉俊 生物 科技 有限 公司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

**GRANT OF WAIVER FROM STRICT COMPLIANCE
WITH RULE 13.46(2)(a) OF THE LISTING RULES**

Reference is made to the announcement of Wai Chun Bio-Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 21 October 2022 in relation to, among other things, further delay in publication of audited annual results of the Group for the eighteen months ended 30 June 2022 and annual report of the Company, and proposed application for waiver from strict compliance with Rule 13.46(2)(a) of the Listing Rules (the “**Announcement**”). Capitalised terms used herein shall have the same meaning as those defined in the Announcement unless stated otherwise.

As set out in the Announcement, the outbreak of COVID-19 in Shandong Province continues in October 2022 and that it continues to affect the audit process of the PRC Subsidiaries. After communicating with the Auditors, on the assumption that the Measures implemented by the local government could be mostly eased or lifted near or before the end of October 2022, the Auditors will require two more weeks to complete their audit work. On this basis, the Company estimates that the publication of the audited annual results of the Group for the eighteen months ended 30 June 2022 would be made on or before 14 November 2022 and the despatch of the annual report to the shareholders of the Company would be made on or before 28 November 2022 as additional time is required to, among other things, prepare the information for inclusion in the annual report for complying with the provisions set out in Appendix 16 to the Listing Rules, and arrange bulk-printing of the annual report.

According to the requirement under Rule 13.46(2)(a) of the Listing Rules, the Company is required to send annual report to its shareholders not later than four months from the end of the financial year. The Company applied to The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) for waiver from strict compliance with Rule 13.46(2)(a) of the Listing Rule, and the Stock Exchange has granted to the Company a waiver from strict compliance with Rule 13.46(2)(a) of the Listing Rules on 4 November 2022 on the condition that the Company will despatch its annual report on or before 28 November 2022. The Stock Exchange may withdraw or change the waiver if the Company’s situation changes.

By Order of the Board
Wai Chun Bio-Technology Limited
Chan Cheuk Ho
Executive Director

Hong Kong, 7 November 2022

As at the date of this announcement, the Board consists of one executive Director, namely Mr. Chan Cheuk Ho and two independent non-executive Directors, namely Mr. Wan Bo and Ms. Hong Ting.